Brian Cheng
Stock Analyst at JP Morgan
(2.18)
# 2,841
Out of 5,154 analysts
75
Total ratings
41.94%
Success rate
-2.42%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARA Protara Therapeutics | Initiates: Overweight | $27 | $5.90 | +357.63% | 1 | Mar 4, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Overweight | $29 | $14.38 | +101.67% | 1 | Mar 2, 2026 | |
| TGTX TG Therapeutics | Maintains: Overweight | $49 → $46 | $29.27 | +57.16% | 1 | Feb 2, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $92 → $122 | $98.40 | +23.98% | 2 | Feb 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $125 | $83.49 | +49.72% | 1 | Dec 10, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.18 | - | 1 | Nov 20, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $68 → $81 | $92.09 | -12.04% | 6 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Underweight | $12 → $5 | $13.44 | -62.80% | 5 | Nov 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $20 → $18 | $11.32 | +59.01% | 5 | Nov 6, 2025 | |
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $24.08 | -4.49% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.30 | - | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.33 | - | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $2.38 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $33 | $26.66 | +23.78% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $47 | $61.88 | -24.05% | 2 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $28.78 | -30.51% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $56.50 | +23.89% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.32 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $21.04 | +4.56% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $23.14 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.00 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $8.10 | +307.41% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.48 | +305.41% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.17 | +8,243.27% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.11 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $320 → $96 | $7.29 | +1,216.87% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.96 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.50 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $7.11 | +1,095.50% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $8.48 | +147.64% | 1 | Aug 3, 2021 |
Protara Therapeutics
Mar 4, 2026
Initiates: Overweight
Price Target: $27
Current: $5.90
Upside: +357.63%
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $29
Current: $14.38
Upside: +101.67%
TG Therapeutics
Feb 2, 2026
Maintains: Overweight
Price Target: $49 → $46
Current: $29.27
Upside: +57.16%
Revolution Medicines
Feb 2, 2026
Maintains: Overweight
Price Target: $92 → $122
Current: $98.40
Upside: +23.98%
Kymera Therapeutics
Dec 10, 2025
Maintains: Overweight
Price Target: $70 → $125
Current: $83.49
Upside: +49.72%
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.18
Upside: -
Protagonist Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $68 → $81
Current: $92.09
Upside: -12.04%
Intellia Therapeutics
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $13.44
Upside: -62.80%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $20 → $18
Current: $11.32
Upside: +59.01%
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $24.08
Upside: -4.49%
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.30
Upside: -
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.33
Upside: -
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.38
Upside: -
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $26.66
Upside: +23.78%
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $61.88
Upside: -24.05%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $28.78
Upside: -30.51%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $56.50
Upside: +23.89%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.32
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $21.04
Upside: +4.56%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $23.14
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.00
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $8.10
Upside: +307.41%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.48
Upside: +305.41%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.17
Upside: +8,243.27%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.11
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $320 → $96
Current: $7.29
Upside: +1,216.87%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $0.96
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.50
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $7.11
Upside: +1,095.50%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $8.48
Upside: +147.64%